What is the 13F Pro Quality Score for GTBP?

13F Pro ranks GT Biopharma, Inc. (GTBP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GTBP's current score at https://13fpro.ai/research/GTBP (free sign-up required for the full ranking).

Where does 13F Pro source GTBP data?

All GT Biopharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. GT Biopharma, Inc. files with the SEC under CIK 109657. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GTBP in?

GT Biopharma, Inc. (GTBP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GTBP research updated on 13F Pro?

GTBP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GT Biopharma, Inc.(GTBP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 109657 GTBP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 41 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

GTBP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for GT Biopharma, Inc. (GTBP), a Healthcare sector company. GTBP is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 41 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), GT Biopharma, Inc. reports net income of $-2.8M, free cash flow of $-2.5M. Top institutional holders of GTBP by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, VANGUARD FIDUCIARY CO, based on the most recent SEC filings. GTBP trades on the Nasdaq exchange and files with the SEC under CIK 109657. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GTBP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GT Biopharma, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-2.8M

Free Cash Flow

Q1 2026

$-2.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2024

FY21 —FY22 —FY23 —FY24 —

Net Income

-73.3% YoY

$-13.2MFY 2024

FY21 $-58.0MFY22 $-20.9MFY23 $-7.6MFY24 $-13.2M

Operating Income

-5.8% YoY

$-14.4MFY 2024

FY21 $-57.5MFY22 $-21.3MFY23 $-13.6MFY24 $-14.4M

EPS (Diluted)

-23.0% YoY

$-6.94FY 2024

FY21 —FY22 $-19.66FY23 $-5.64FY24 $-6.94

Total Assets

-70.0% YoY

$4.2MFY 2024

FY21 $32.2MFY22 $16.7MFY23 $14.1MFY24 $4.2M

Op. Cash Flow

-45.8% YoY

$-12.9MFY 2024

FY21 $-15.6MFY22 $-15.2MFY23 $-8.9MFY24 $-12.9M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019	FY 2018
Revenue	—	—	—	—	$0.00	—
Net Income	$-13.2M -73.3%	$-7.6M +63.6%	$-20.9M +64.0%	$-58.0M -50.1%	$-38.6M +85.1%	$-259.2M
Operating Income	$-14.4M -5.8%	$-13.6M +36.1%	$-21.3M +63.0%	$-57.5M -458.2%	$16.1M +106.4%	$-250.1M
EPS (Diluted)	$-6.94 -23.0%	$-5.64 +71.3%	$-19.66	—	—	$-5.16
Total Assets	$4.2M -70.0%	$14.1M -15.7%	$16.7M -48.0%	$32.2M +8023.5%	$396.0K -98.4%	$25.4M
Operating Cash Flow	$-12.9M -45.8%	$-8.9M +41.8%	$-15.2M +2.5%	$-15.6M -326.5%	$-3.7M +65.7%	$-10.7M

AI Insight: GTBP Financial Trends

GT Biopharma remains unprofitable with volatile quarterly swings; equity turned positive in latest quarter but operational losses persist.

• Net income swung from -$30M loss in Q2 2025 to +$8M gain in Q3 2025, then returned to -$3M loss in Q1 2026.

• Operating cash flow consistently negative across all eight quarters, ranging -$2M to -$4M per quarter.

• Equity recovered to +$8M in Q1 2026 from -$26M low in Q2 2025, suggesting capital raise or asset revaluation.

⚠ No revenue reported across entire period; company appears pre-commercial or in clinical/development phase.

⚠ Operating income deteriorated to -$6M in Q4 2025, highest loss since Q2 2024, before improving to -$3M in Q1 2026.

⚠ Persistent negative operating cash flow unsustainable without revenue generation or additional financing.

AI Insight: GTBP Ratio Trends

Insufficient data: only ROE is populated (−149.5% in Q1 2026), rendering trend analysis impossible.

• ROE collapsed to −149.5% in Q1 2026, indicating substantial net loss relative to equity.

⚠ All other profitability and efficiency metrics (OpMargin, NPM, ROA, ROIC, D/E) are missing; cannot assess operational health or leverage.

Get alerted when GTBP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GT Biopharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GTBP

VANGUARD CAPITAL MANAGEMENT LLC
$184.4K451,875 sh
GEODE CAPITAL MANAGEMENT, LLC
$120.2K294,459 sh
VANGUARD FIDUCIARY TRUST CO
$92.2K225,938 sh
SRS Capital Advisors, Inc.
$38.2K93,627 sh
CITADEL ADVISORS LLC
$27.0K66,165 sh
SeaCrest Wealth Management, LLC
$20.4K50,000 sh
UBS Group AG
$18.8K45,970 sh
TWO SIGMA SECURITIES, LLC
$13.0K31,796 sh
LPL Financial LLC
$12.4K30,382 sh
Invst, LLC
$9.6K23,400 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$184.4K	451,875
GEODE CAPITAL MANAGEMENT, LLC	$120.2K	294,459
VANGUARD FIDUCIARY TRUST CO	$92.2K	225,938
SRS Capital Advisors, Inc.	$38.2K	93,627
CITADEL ADVISORS LLC	$27.0K	66,165
SeaCrest Wealth Management, LLC	$20.4K	50,000
UBS Group AG	$18.8K	45,970
TWO SIGMA SECURITIES, LLC	$13.0K	31,796
LPL Financial LLC	$12.4K	30,382
Invst, LLC	$9.6K	23,400

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GTBP on your watchlist

Track score changes the day GT Biopharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GTBP a good stock to buy?

13F Pro's AI-powered analysis of GT Biopharma, Inc. (GTBP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GTBP are available on the GTBP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GTBP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GTBP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GT Biopharma, Inc.'s investment landscape.